Cost-Effectiveness of Corneal Collagen Crosslinking for Progressive Keratoconus in Brazil
Author Information
Author(s): Hansen Lucca Ortolan, Garcia Renato, Torricelli André Augusto Miranda, Bechara Samir Jacob
Primary Institution: University of São Paulo
Hypothesis
Is corneal collagen crosslinking (CXL) more cost-effective than conventional treatment for progressive keratoconus in Brazil?
Conclusion
Corneal collagen CXL is a highly cost-effective intervention for progressive keratoconus within the Brazilian Unified Health System.
Supporting Evidence
- CXL demonstrated superior cost-effectiveness compared to conventional treatment.
- The incremental cost-effectiveness ratio was USD 58.26/QALY gained.
- CXL significantly reduced the number of required corneal transplants.
- The mean incremental net monetary benefit was USD 11,613.82.
Takeaway
This study shows that a special eye treatment called CXL is cheaper and better for people with a condition called keratoconus compared to regular treatments.
Methodology
A lifetime microsimulation model was used to compare costs and quality-adjusted life years for patients undergoing CXL or conventional treatment.
Potential Biases
The model may not apply to other populations or Brazil's private health system due to regional differences.
Limitations
The study relied on international data due to limited local data on keratoconus, which may underestimate transplant failure rates and costs.
Participant Demographics
Simulated groups of 5000 18-year-old patients with progressive keratoconus.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI: 58.17–58.36
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website